Predictive Oncology Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement

NEXT STORY
Innovation Pharmaceuticals and FDA Agree to Waive Initial Pediatric Study Plan Requirement Regarding Brilacidin for the Prevention of Oral Mucositis
PREV STORY
Surface Oncology Announces $25 Million Debt Financing from K2 HealthVentures
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Aquestive Therapeutics Receives Notification from FDA that It Will Not Be Ready to Take Action by December 23, 2021 for the Company’s NDA for Libervant™ (diazepam) Buccal Film

author_avatar
NASDAQ Market News

Onconova Therapeutics Announces Plan for Expanding Rigosertib Clinical Trials for Patients with Myelodysplastic Syndromes (MDS) to South America with Pint Pharma

Pint Pharma to facilitate expansion of Phase 3 INSPIRE trial to Argentina, Chile, and ...

author_avatar
NASDAQ Market News

QuestCap Enters Binding Agreement to Acquire 30% Interest in Glenco Medical

author_avatar
NASDAQ Market News